WO2002103320A3 - Diagnosis and prognosis of breast cancer patients - Google Patents

Diagnosis and prognosis of breast cancer patients Download PDF

Info

Publication number
WO2002103320A3
WO2002103320A3 PCT/US2002/018947 US0218947W WO02103320A3 WO 2002103320 A3 WO2002103320 A3 WO 2002103320A3 US 0218947 W US0218947 W US 0218947W WO 02103320 A3 WO02103320 A3 WO 02103320A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
relates
diagnosis
prognosis
whose expression
Prior art date
Application number
PCT/US2002/018947
Other languages
French (fr)
Other versions
WO2002103320A2 (en
Inventor
Hongyue Dai
Yudong He
Peter S Linsley
Mao Mao
Christopher J Roberts
T Veer Laura Johanna Van
De Vijver Marc J Van
Rene Bernards
A A M Hart
Original Assignee
Rosetta Inpharmatics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Inpharmatics Inc filed Critical Rosetta Inpharmatics Inc
Priority to DK02746538.4T priority Critical patent/DK1410011T3/en
Priority to CA2451074A priority patent/CA2451074C/en
Priority to PT02746538T priority patent/PT1410011E/en
Priority to JP2003505588A priority patent/JP2005500832A/en
Priority to EP02746538A priority patent/EP1410011B1/en
Priority to AT02746538T priority patent/ATE503023T1/en
Priority to DE60239535T priority patent/DE60239535D1/en
Priority to AU2002316251A priority patent/AU2002316251A1/en
Publication of WO2002103320A2 publication Critical patent/WO2002103320A2/en
Publication of WO2002103320A3 publication Critical patent/WO2002103320A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.
PCT/US2002/018947 2001-06-18 2002-06-14 Diagnosis and prognosis of breast cancer patients WO2002103320A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DK02746538.4T DK1410011T3 (en) 2001-06-18 2002-06-14 Diagnosis and prognosis of breast cancer patients
CA2451074A CA2451074C (en) 2001-06-18 2002-06-14 Diagnosis and prognosis of breast cancer patients
PT02746538T PT1410011E (en) 2001-06-18 2002-06-14 Diagnosis and prognosis of breast cancer patients
JP2003505588A JP2005500832A (en) 2001-06-18 2002-06-14 Diagnosis and prognosis of breast cancer patients
EP02746538A EP1410011B1 (en) 2001-06-18 2002-06-14 Diagnosis and prognosis of breast cancer patients
AT02746538T ATE503023T1 (en) 2001-06-18 2002-06-14 DIAGNOSIS AND PROGNOSIS OF BREAST CANCER PATIENTS
DE60239535T DE60239535D1 (en) 2001-06-18 2002-06-14 DIAGNOSIS AND FORECASTING BREAST CANCER PATIENTS
AU2002316251A AU2002316251A1 (en) 2001-06-18 2002-06-14 Diagnosis and prognosis of breast cancer patients

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29891801P 2001-06-18 2001-06-18
US60/298,918 2001-06-18
US38071002P 2002-05-14 2002-05-14
US60/380,710 2002-05-14

Publications (2)

Publication Number Publication Date
WO2002103320A2 WO2002103320A2 (en) 2002-12-27
WO2002103320A3 true WO2002103320A3 (en) 2003-07-31

Family

ID=26970946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/018947 WO2002103320A2 (en) 2001-06-18 2002-06-14 Diagnosis and prognosis of breast cancer patients

Country Status (11)

Country Link
US (5) US7514209B2 (en)
EP (1) EP1410011B1 (en)
JP (2) JP2005500832A (en)
AT (1) ATE503023T1 (en)
AU (1) AU2002316251A1 (en)
CA (1) CA2451074C (en)
CY (1) CY1111677T1 (en)
DE (1) DE60239535D1 (en)
DK (1) DK1410011T3 (en)
PT (1) PT1410011E (en)
WO (1) WO2002103320A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102575285A (en) * 2009-04-20 2012-07-11 柯蓝 Breast cancer susceptibility gene GT198 and uses thereof

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US20040241726A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of allergies related gene transcripts in blood
US20040265868A1 (en) * 1999-01-06 2004-12-30 Chondrogene Limited Method for the detection of depression related gene transcripts in blood
US20040248170A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of hyperlipidemia related gene transcripts in blood
US7473528B2 (en) * 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US20060134635A1 (en) * 2001-02-28 2006-06-22 Chondrogene Limited Method for the detection of coronary artery disease related gene transcripts in blood
US20040248169A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of obesity related gene transcripts in blood
US20040241728A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of lung disease related gene transcripts in blood
US20030216558A1 (en) * 2000-12-22 2003-11-20 Morris David W. Novel compositions and methods for cancer
AUPR278301A0 (en) 2001-01-31 2001-02-22 Bionomics Limited A novel gene
US7026121B1 (en) * 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
CA2451074C (en) * 2001-06-18 2014-02-11 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
US20030104426A1 (en) * 2001-06-18 2003-06-05 Linsley Peter S. Signature genes in chronic myelogenous leukemia
ES2390531T3 (en) * 2001-09-18 2012-11-13 Genentech, Inc. Compositions and procedures for the diagnosis and treatment of tumor
WO2003030725A2 (en) * 2001-10-11 2003-04-17 The Johns Hopkins University Pancreatic cancer diagnosis and therapies
US20040009495A1 (en) * 2001-12-07 2004-01-15 Whitehead Institute For Biomedical Research Methods and products related to drug screening using gene expression patterns
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
CN1643163A (en) * 2002-02-20 2005-07-20 Ncc技术投资私人有限公司 Materials and methods relating to cancer diagnosis
EP2241636A1 (en) 2002-03-13 2010-10-20 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
JP4585968B2 (en) * 2002-05-10 2010-11-24 パーデュー・リサーチ・ファウンデーション EphA2 agonist monoclonal antibody and method of use thereof
US8008003B2 (en) 2002-11-15 2011-08-30 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2004058050A2 (en) * 2002-12-20 2004-07-15 Avalon Pharmaceuticals Amplified cancer target genes useful in diagnosis and therapeutic screening
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US20070149449A1 (en) * 2003-02-14 2007-06-28 Morris David W Therapeutic targets in cancer
DE602004017426D1 (en) * 2003-02-20 2008-12-11 Genomic Health Inc USE OF INTRONIC RNA SEQUENCES FOR THE QUANTIFICATION OF GENE EXPRESSION
WO2004079014A2 (en) * 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc Epha2 and non-neoplastic hyperproliferative cell disorders
US7892745B2 (en) * 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20060263813A1 (en) * 2005-05-11 2006-11-23 Expression Diagnostics, Inc. Methods of monitoring functional status of transplants using gene panels
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
JP2007515945A (en) * 2003-05-30 2007-06-21 ロゼッタ インファーマティックス エルエルシー Methods for identifying modulators of kinesin activity
US7604799B2 (en) 2003-06-06 2009-10-20 Medimmune, Llc EphA4 Antibodies
EP1651775A2 (en) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
ES2609234T3 (en) 2003-06-24 2017-04-19 Genomic Health, Inc. Prediction of the probability of cancer recurrence
EP1644858B1 (en) 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20050112622A1 (en) 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
ES2311852T3 (en) * 2003-08-28 2009-02-16 Ipsogen IDENTIFICATION OF A SPECIFIC MODEL OF THE ERBB2 GENE EXPRESSION IN CANCER OF BREAST
GB0320648D0 (en) * 2003-09-03 2003-10-01 Randox Lab Ltd Molecular marker
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
AU2004274973A1 (en) * 2003-09-19 2005-03-31 Aviaradx, Inc. Predicting breast cancer treatment outcome
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
GB0323226D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer diagnosis
EP1892306A3 (en) * 2003-10-06 2008-06-11 Bayer HealthCare AG Methods and kits for investigating cancer
CA2551267C (en) 2003-12-23 2012-05-01 Genomic Health, Inc. Universal amplification of fragmented rna
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005083429A2 (en) * 2004-02-20 2005-09-09 Veridex, Llc Breast cancer prognostics
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
JP2007527247A (en) * 2004-03-05 2007-09-27 ロゼッタ インファーマティクス エルエルシー Classification of breast cancer patients using a combination of clinical criteria and informative gene sets
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
EP2163650B1 (en) 2004-04-09 2015-08-05 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005106044A1 (en) * 2004-04-23 2005-11-10 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
WO2005118879A2 (en) * 2004-06-04 2005-12-15 Arcturus Bioscience, Inc. Identification of tumors
US20120258442A1 (en) * 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
TWI661199B (en) 2004-07-23 2019-06-01 太平洋愛吉生技股份有限公司 Urine markers for detection of bladder cancer
EP1782315A4 (en) * 2004-07-30 2009-06-24 Rosetta Inpharmatics Llc Prognosis of breast cancer patients
EP1627923A1 (en) * 2004-08-18 2006-02-22 Het Nederlands Kanker Instituut Means and methods for detecting and/or staging a follicular lymphoma cells
WO2006029184A2 (en) * 2004-09-08 2006-03-16 Expression Diagnostics, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
JP5184087B2 (en) * 2004-09-22 2013-04-17 トリパス イメージング， インコーポレイテッド Methods and computer program products for analyzing and optimizing marker candidates for cancer prognosis
GB0421838D0 (en) 2004-09-30 2004-11-03 Congenia S R L Cancer markers
US8747867B2 (en) 2004-09-30 2014-06-10 Ifom Fondazione Instituto Firc Di Oncologia Molecolare Cancer markers
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
DK1836629T3 (en) 2004-11-05 2020-05-18 Genomic Health Inc PREDICTION OF RESPONSE TO CHEMOTHERAPY USING MARKERS FOR GENEPRESSION
AU2005304878B2 (en) 2004-11-05 2010-07-08 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
CA2592993C (en) * 2004-12-13 2013-06-18 National University Corporation Okayama University Method for detecting methylation in genes and method for examining neoplasm through detecting methylation in genes
US20060183893A1 (en) * 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells
WO2006090389A2 (en) * 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
WO2006110264A2 (en) * 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
DE102005013846A1 (en) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US20090047282A1 (en) * 2005-03-25 2009-02-19 Hideaki Tojo Prophylactic/Therapeutic Agent for Cancer
EP2365092A1 (en) 2005-06-03 2011-09-14 Aviaradx, Inc. Identification of tumors and tissues
AU2006254874A1 (en) * 2005-06-08 2006-12-14 Carefusion 303, Inc. System and method for dynamic determination of disease prognosis
EP1946118A4 (en) * 2005-11-10 2009-01-21 Aurelium Biopharma Inc Tissue diagnostics for breast cancer
US8014957B2 (en) * 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US20100137163A1 (en) 2006-01-11 2010-06-03 Link Darren R Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors
NZ545243A (en) * 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US20090098538A1 (en) * 2006-03-31 2009-04-16 Glinsky Gennadi V Prognostic and diagnostic method for disease therapy
WO2008051290A2 (en) * 2006-04-07 2008-05-02 Xdx, Inc. Steroid responsive nucleic acid expression and prediction of disease activity
US7789081B2 (en) * 2006-04-20 2010-09-07 Whirlpool Corporation Modular frame chassis for cooking range
US20080003142A1 (en) 2006-05-11 2008-01-03 Link Darren R Microfluidic devices
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
DE102006027818A1 (en) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative diseases
DE602007013405D1 (en) * 2006-07-14 2011-05-05 Us Government METHOD FOR DETERMINING THE PROGNOSIS OF ADENOCARCINOMA
US9012390B2 (en) 2006-08-07 2015-04-21 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
US7993832B2 (en) * 2006-08-14 2011-08-09 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
EP2090588A4 (en) 2006-10-23 2010-04-07 Neocodex S L In vitro method for prognosis and/or diagnosis of hypersensitivity to ooestrogens or to substances with ooestrogenic activity
KR100862972B1 (en) 2006-10-30 2008-10-13 한국과학기술연구원 Biomaker and screening method of volatile organic compounds having toxicity using thereof
WO2008140484A2 (en) * 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
WO2008073578A2 (en) 2006-12-08 2008-06-19 Iowa State University Research Foundation, Inc. Plant genes involved in nitrate uptake and metabolism
CA2672270A1 (en) * 2006-12-15 2008-06-26 Gennadi V. Glinksy Treatments of therapy resistant diseases and drug combinations for treating the same
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8030060B2 (en) * 2007-03-22 2011-10-04 West Virginia University Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
US20090062144A1 (en) * 2007-04-03 2009-03-05 Nancy Lan Guo Gene signature for prognosis and diagnosis of lung cancer
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
KR100886937B1 (en) 2007-06-21 2009-03-09 주식회사 랩 지노믹스 BRCA1 and BRCA2 germline mutations useful for predicting or detecting breast cancer or ovarian cancer
JP5303132B2 (en) * 2007-09-20 2013-10-02 シスメックス株式会社 Method and apparatus for determining the presence or absence of cancer cells
EP2093567A1 (en) * 2008-02-21 2009-08-26 Pangaea Biotech, S.A. Brca1 mRNA expression levels predict survival in breast cancer patients treated with neoadjuvant chemotherapy
US20110053804A1 (en) * 2008-04-03 2011-03-03 Sloan-Kettering Institute For Cancer Research Gene Signatures for the Prognosis of Cancer
ES2338843B1 (en) 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas GENOMIC FOOTPRINT OF CANCER OF MAMA.
WO2010009365A1 (en) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Droplet libraries
EP2159291A1 (en) 2008-09-01 2010-03-03 Agendia B.V. Means and method for determining tumor cell percentage in a sample
EP2202320A1 (en) * 2008-12-24 2010-06-30 Agendia B.V. Methods and means for typing a sample comprising colorectal cancer cells
US20100204973A1 (en) * 2009-01-15 2010-08-12 Nodality, Inc., A Delaware Corporation Methods For Diagnosis, Prognosis And Treatment
EP3415235A1 (en) 2009-03-23 2018-12-19 Raindance Technologies Inc. Manipulation of microfluidic droplets
EP2241634A1 (en) * 2009-04-16 2010-10-20 Université Libre de Bruxelles Diagnostic method and tools to predict the effiacy of targeted agents against IGF-1 pathway activation in cancer
US8637240B2 (en) * 2009-09-28 2014-01-28 Institute For Systems Biology Use of gene expression signatures to determine cancer grade
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
CA2777417A1 (en) * 2009-10-21 2011-04-28 Basf Plant Science Company Gmbh Method for generating biomarker reference patterns
US20130029926A1 (en) * 2009-11-05 2013-01-31 Myriad Genetics, Inc. Compositions and methods for determing cancer susceptibility
WO2011063274A2 (en) * 2009-11-23 2011-05-26 Genomic Health, Inc. Methods to predict clinical outcome of cancer
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
EP2524055A4 (en) 2010-01-11 2013-06-05 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2011100604A2 (en) 2010-02-12 2011-08-18 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
JP5725274B2 (en) 2010-04-22 2015-05-27 国立大学法人大阪大学 Breast cancer prognosis testing method
BR112012017649A2 (en) 2010-04-22 2015-09-15 Toray Industries "Method for preparing rna and gene expression analysis with an rna sample"
EP3447155A1 (en) 2010-09-30 2019-02-27 Raindance Technologies, Inc. Sandwich assays in droplets
US20140030255A1 (en) * 2010-11-03 2014-01-30 Merck Sharp & Dohme Corp. Methods of predicting cancer cell response to therapeutic agents
US10011876B2 (en) * 2010-11-23 2018-07-03 Krisani Biosciences Pvt. Ltd Method and system for prognosis and treatment of diseases using portfolio of genes
WO2012079059A2 (en) 2010-12-09 2012-06-14 Biotheranostics, Inc. Post-treatment breast cancer prognosis
US9402865B2 (en) * 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
US9364803B2 (en) 2011-02-11 2016-06-14 Raindance Technologies, Inc. Methods for forming mixed droplets
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
EP2694963B1 (en) 2011-04-01 2017-08-02 Qiagen Gene expression signature for wnt/b-catenin signaling pathway and use thereof
WO2012167142A2 (en) 2011-06-02 2012-12-06 Raindance Technolgies, Inc. Enzyme quantification
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8748587B2 (en) 2011-06-02 2014-06-10 Novartis Ag Molecules and methods for modulating TMEM16A activities
WO2012177945A2 (en) * 2011-06-21 2012-12-27 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
US9175351B2 (en) 2011-07-13 2015-11-03 Agendia N.V. Means and methods for molecular classification of breast cancer
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013025952A2 (en) * 2011-08-16 2013-02-21 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of breast cancer
EP3495817A1 (en) 2012-02-10 2019-06-12 Raindance Technologies, Inc. Molecular diagnostic screening assay
WO2013155567A1 (en) * 2012-04-20 2013-10-24 Mat Malta Advanced Technologies Limited Sex determination genes
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
US9045546B2 (en) 2012-05-31 2015-06-02 Novartis Ag Molecules and methods for modulating TMEM16A activities
US9758829B2 (en) 2012-06-22 2017-09-12 Htg Molecular Diagnostics, Inc. Molecular malignancy in melanocytic lesions
WO2014038524A1 (en) * 2012-09-05 2014-03-13 和光純薬工業株式会社 Method for determining breast cancer
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
JP2016521979A (en) 2013-05-30 2016-07-28 ジェノミック ヘルス， インコーポレイテッド Gene expression profiling algorithm for calculating recurrence score for patients with kidney cancer
CN105706097A (en) 2013-06-28 2016-06-22 南托米克斯有限责任公司 Pathway analysis for identification of diagnostic tests
CN105745659A (en) 2013-09-16 2016-07-06 佰欧迪塞克斯公司 Classifier generation method using combination of mini-classifiers with regularization and uses thereof
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
WO2015080585A1 (en) 2013-11-28 2015-06-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Methods for molecular classification of brca-like breast and/or ovarian cancer
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10370719B2 (en) * 2014-11-12 2019-08-06 Hitachi Chemical Co., Ltd. Method and device for diagnosing organ injury
US10980519B2 (en) 2015-07-14 2021-04-20 Duke University Systems and methods for extracting prognostic image features
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
WO2017083675A1 (en) 2015-11-13 2017-05-18 Biotheranostics, Inc. Integration of tumor characteristics with breast cancer index
EP3402572B1 (en) 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US10934590B2 (en) 2016-05-24 2021-03-02 Wisconsin Alumni Research Foundation Biomarkers for breast cancer and methods of use thereof
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3730941A1 (en) * 2019-04-23 2020-10-28 Institut Jean Paoli & Irène Calmettes Method for determining a reference tumor aggressiveness molecular gradient for a pancreatic ductal adenocarcinoma
US20230330223A1 (en) 2020-04-27 2023-10-19 Agendia N.V. Treatment of her2 negative, mammaprint high risk 2 breast cancer
US20220042106A1 (en) 2020-08-06 2022-02-10 Agendia NV Systems and methods of using cell-free nucleic acids to tailor cancer treatment
US20220042108A1 (en) 2020-08-06 2022-02-10 Agendia NV Systems and methods of assessing breast cancer
CN112927795B (en) * 2021-02-23 2022-09-23 山东大学 Breast cancer prediction system based on bagging algorithm
WO2023224487A1 (en) 2022-05-19 2023-11-23 Agendia N.V. Prediction of response to immune therapy in breast cancer patients
WO2023224488A1 (en) 2022-05-19 2023-11-23 Agendia N.V. Dna repair signature and prediction of response following cancer therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107034A (en) * 1998-03-09 2000-08-22 The Board Of Trustees Of The Leland Stanford Junior University GATA-3 expression in human breast carcinoma
US6342483B1 (en) * 1994-01-14 2002-01-29 Vanderbilt University Method for detection and treatment of breast cancer
US6342491B1 (en) * 1991-05-21 2002-01-29 American Home Products Corporation Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
US6358682B1 (en) * 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6455300B1 (en) * 1995-12-08 2002-09-24 Han Htun Method and compositions for monitoring DNA binding molecules in living cells

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5677125A (en) 1994-01-14 1997-10-14 Vanderbilt University Method of detection and diagnosis of pre-invasive cancer
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
ATE270712T1 (en) 1995-03-17 2004-07-15 Wayne John Cancer Inst DETECTION OF MELANOMA METASTASIS USING A MULTIPLE MARKER TEST
CA2279361A1 (en) 1997-01-31 1998-08-06 Fred Hutchinson Cancer Research Center Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin e
US6028189A (en) 1997-03-20 2000-02-22 University Of Washington Solvent for oligonucleotide synthesis and methods of use
NO972006D0 (en) * 1997-04-30 1997-04-30 Forskningsparken I Aas As New method for diagnosis of diseases
US6432707B1 (en) 1997-12-24 2002-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6203987B1 (en) 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US7648826B1 (en) * 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
US6647341B1 (en) 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
AU6213600A (en) 1999-07-16 2001-02-05 Rosetta Inpharmatics, Inc. Methods for determining the specificity and sensitivity of oligonucleotides for hybridization
US7013221B1 (en) 1999-07-16 2006-03-14 Rosetta Inpharmatics Llc Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
AU2596901A (en) 1999-12-21 2001-07-03 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001229340A1 (en) 2000-01-14 2001-07-24 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2002008261A2 (en) * 2000-07-26 2002-01-31 Stanford University Bstp-trans protein and related reagents and methods of use thereof
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
US6713257B2 (en) 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
US20030215805A1 (en) 2001-04-20 2003-11-20 Millennium Pharmaceutical, Inc. Novel genes, compositions, kits, and methods for identification, assessment prevention, and therapy of breast cancer
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
CA2451074C (en) 2001-06-18 2014-02-11 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
EP1644858B1 (en) 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
JP2007527247A (en) 2004-03-05 2007-09-27 ロゼッタ インファーマティクス エルエルシー Classification of breast cancer patients using a combination of clinical criteria and informative gene sets
EP1782315A4 (en) 2004-07-30 2009-06-24 Rosetta Inpharmatics Llc Prognosis of breast cancer patients
WO2006084272A2 (en) 2005-02-04 2006-08-10 Rosetta Inpharmatics Llc Methods of predicting chemotherapy responsiveness in breast cancer patients

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342491B1 (en) * 1991-05-21 2002-01-29 American Home Products Corporation Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
US6342483B1 (en) * 1994-01-14 2002-01-29 Vanderbilt University Method for detection and treatment of breast cancer
US6455300B1 (en) * 1995-12-08 2002-09-24 Han Htun Method and compositions for monitoring DNA binding molecules in living cells
US6358682B1 (en) * 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6107034A (en) * 1998-03-09 2000-08-22 The Board Of Trustees Of The Leland Stanford Junior University GATA-3 expression in human breast carcinoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LAIRD ET AL: "Deficiency of Connexin43 gap junctions is an independent marker for breast tumors", CANCER RESEARCH, vol. 59, 15 August 1999 (1999-08-15), pages 4104 - 4110, XP002963203 *
SORLIE ET AL: "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", PROC NAT ACAD OF SCI USA, vol. 98, no. 19, 11 September 2001 (2001-09-11), pages 10869 - 10874, XP002215483 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102575285A (en) * 2009-04-20 2012-07-11 柯蓝 Breast cancer susceptibility gene GT198 and uses thereof
CN102575285B (en) * 2009-04-20 2014-04-02 柯蓝 Breast cancer susceptibility gene GT198 and uses thereof

Also Published As

Publication number Publication date
DK1410011T3 (en) 2011-07-18
EP1410011B1 (en) 2011-03-23
US7514209B2 (en) 2009-04-07
WO2002103320A2 (en) 2002-12-27
US20180305768A1 (en) 2018-10-25
JP2005500832A (en) 2005-01-13
US20090157326A1 (en) 2009-06-18
JP5237076B2 (en) 2013-07-17
JP2009131262A (en) 2009-06-18
PT1410011E (en) 2011-07-25
CY1111677T1 (en) 2015-10-07
CA2451074A1 (en) 2002-12-27
US20030224374A1 (en) 2003-12-04
US20130116145A1 (en) 2013-05-09
DE60239535D1 (en) 2011-05-05
EP1410011A4 (en) 2007-08-01
US20110301048A1 (en) 2011-12-08
US9909185B2 (en) 2018-03-06
CA2451074C (en) 2014-02-11
AU2002316251A1 (en) 2003-01-02
US7863001B2 (en) 2011-01-04
EP1410011A2 (en) 2004-04-21
ATE503023T1 (en) 2011-04-15

Similar Documents

Publication Publication Date Title
WO2002103320A3 (en) Diagnosis and prognosis of breast cancer patients
WO2004065545A3 (en) Diagnosis and prognosis of breast cancer patients
WO2006015312A3 (en) Prognosis of breast cancer patients
Bläker et al. The association between mutations in BRAF and colorectal cancer–specific survival depends on microsatellite status and tumor stage
Clarke et al. Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer
Schlomm et al. Clinical significance of p53 alterations in surgically treated prostate cancers
Park et al. Notch3 gene amplification in ovarian cancer
Sidransky Emerging molecular markers of cancer
Massagué Sorting out breast-cancer gene signatures
Frattini et al. Different genetic features associated with colon and rectal carcinogenesis
Hiyama et al. Genetic polymorphisms and esophageal cancer risk
Li et al. BRAF mutation in papillary thyroid carcinoma
Zhang et al. Glutathione S‐transferase T1 and M1 genotypes in normal mucosa, transitional mucosa and colorectal adenocarcinoma
WO2006133923A3 (en) Diagnosis, prognosis and prediction of recurrence of breast cancer
Sushma et al. PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south Indian population
Wang et al. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression
Mokarram et al. Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O 6-MGMT) promoter regions in colorectal cancer
Sinha et al. Significance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue
Misawa et al. Site‐specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis
Rubin et al. Bioinformatics approach leads to the discovery of the TMPRSS2: ETS gene fusion in prostate cancer
Lin et al. Klotho‐beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
Zolotov Genetic testing in differentiated thyroid carcinoma: Indications and clinical implications
Sun et al. Hypermethylated PAX1 and ZNF582 genes in the tissue sample are associated with aggressive progression of oral squamous cell carcinoma
Al-Temaimi et al. Reduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer
Karim et al. Molecular analysis of V617F mutation in Janus kinase 2 gene of breast cancer patients

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2451074

Country of ref document: CA

Ref document number: 2003505588

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002746538

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002746538

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642